Experimental Therapeutic Solutions for Behcet's Disease

Area of Science:

• Immunology
• Genetics
• Rheumatology

Background:

• Behcet's disease (BD) is a chronic systemic vasculitis characterized by recurrent inflammation affecting multiple organs.
• Mucocutaneous lesions, such as oral and genital ulcers, are common early symptoms crucial for timely diagnosis and management.
• Genetic factors, particularly HLA-B*51, and environmental triggers like microbial agents and microbiome alterations are implicated in BD pathogenesis.

Purpose of the Study:

• To review the current understanding of Behcet's disease etiopathogenesis, focusing on genetic and immunological mechanisms.
• To highlight the importance of early recognition of mucocutaneous lesions for disease management and prevention of major organ involvement.
• To discuss recent advancements in treatment strategies for Behcet's disease, including novel targeted therapies.

Main Methods:

• Review of recent genome-wide association studies (GWAS) identifying genetic predisposing factors like HLA-B*51.
• Analysis of immunological pathways involving antigen-presenting cells (APCs), T-cell responses (Th1, Th17, Treg), and cytokine signaling.
• Evaluation of clinical data on the efficacy and safety of existing and emerging therapeutic agents.

Main Results:

• HLA-B*51 is the most significant genetic risk factor for Behcet's disease.
• Interactions between HLA-B*51 and ERAP1 influence T-cell responses, contributing to disease development.
• Newer treatments, including apremilast and biologics (anti-TNF-α, IL-1, IL-6, IL-17, IL-12/23 antagonists), show high efficacy in managing mucocutaneous and organ-specific manifestations.

Conclusions:

• Early diagnosis of Behcet's disease based on mucocutaneous lesions is critical for preventing severe organ damage.
• Understanding the immunopathogenesis has led to the development of targeted therapies that significantly improve patient outcomes and quality of life.
• Biologics and targeted small molecules offer effective treatment options for patients with severe or refractory Behcet's disease, reducing mortality rates.